QUOTED. 17 July 2019. Peter Shearstone.
Executive Summary
Thermo Fisher Scientific's Peter Shearstone is urging fellow in vitro diagnostic firms to play in the US FDA's Case for Quality Voluntary Improvement Program (CFQ VIP). See what he said here.
"[The IVD industry] has to absolutely get away from being a reactive business. I think we thrive on – maybe as human beings – the excitement of problem-solving and saving the day, but the reality of it is, we have to do a lot more proactive things to avoid the mistakes – the errors – from happening in the first place. I look at … CFQ VIP as a way to move the thinking toward proactivity and getting out of the routine of always going from crisis to crisis." – Peter Shearstone, VP of global quality assurance and regulatory affairs, Thermo Fisher Scientific Inc.
- Find out more: Thermo Fisher VP Wants More IVD Firms Involved In FDA's Manufacturing Maturity Program (Even Though His Company Isn't)
Click here for a free trial of Medtech Insight